Dashenlin Pharm Grp Co Ltd

Dashenlin released its 2026 interim report on August 25, 2026. Total operating revenue was 13.991 billion yuan, and net profit attributable to the parent company was 927 million yuan. Net cash inflow from operating activities was 1.289 billion yuan, a decrease of 1.621 billion yuan compared with the same period last year, down 55.70 percent year on year. The company's latest asset-liability ratio was 65.05 percent, gross margin was 35.60 percent, down 0.45 percentage points from the previous quarter, latest return on equity was 11.98 percent, and diluted earnings per share was 0.81 yuan. The company's latest total asset turnover was 0.53 times, and inventory turnover was 2.17 times, unchanged from the same period last year. The number of shareholders was 25,600, and the top ten shareholders held 848 million shares, accounting for 74.46 percent of total share capital.